• Elobixibat Hydrate: Precision IBAT Translation

  2026-09-20

  A thought-leadership guide to translating Elobixibat hydrate from selective IBAT blockade into measurable gastrointestinal and metabolic outcomes, with practical validation parameters, competitive positioning, and a mechanism-first development strategy.

• 6-OHDA Hydrochloride: Research Workflows

  2026-09-19

  Build reproducible catecholaminergic injury models with 6-OHDA hydrochloride while separating chemical lesion effects from macrophage immunometabolic mechanisms. This workflow connects neurotoxic stress assays with the CH25H–25HC–AMPKα–STAT6 framework reported in Immunity, without treating the two systems as interchangeable.

• JNJ-10198409: Rethinking PDGF Translation

  2026-09-18

  JNJ-10198409 provides a nanomolar research entry point for dissecting PDGF-BB receptor signaling across proliferation, angiogenesis, and fibrosis-relevant models. This thought-leadership guide moves beyond potency claims to show how time-resolved pharmacology, orthogonal validation, and careful cross-domain interpretation can strengthen translational conclusions.

• Troglitazone Workflows for PPARγ Research

  2026-09-18

  Troglitazone is a practical PPARγ agonist for connecting type 2 diabetes research, lipid and glucose metabolism modulation, renal carcinoma assays, and tumor-associated macrophage studies. This workflow-focused guide explains how to prepare the compound, structure concentration-response experiments, and interpret SPP1-related findings without overstating the evidence.

• Ertugliflozin (PF-04971729): SGLT2 Research Guide

  2026-09-17

  Ertugliflozin, also called PF-04971729, is a highly selective SGLT2 inhibitor for glucose reabsorption inhibition and diabetes mellitus research. Its renal mechanism is well established, while cardiovascular and ulcerative-colitis findings require domain-specific interpretation and appropriate controls.

• HyperScribe All in One mRNA Synthesis Kit Plus 1

  2026-09-17

  The HyperScribe All in One mRNA Synthesis Kit Plus 1 is an ARCA capped mRNA synthesis kit for T7-based production of modified, polyadenylated mRNA. Its integrated workflow combines co-transcriptional ARCA capping, 5mCTP and ψUTP incorporation, DNase I treatment, and post-transcriptional poly(A) tailing.

• MDockPeP2_VS: Peptide Inhibitors of β-Lactamase

  2026-09-16

  The 2024 PNAS Nexus study introduces MDockPeP2_VS, an automated structure-based method that reduces the conformational search problem in large-scale peptide screening. Applied to TEM-1 β-lactamase, the workflow identified a short peptide with micromolar inhibitory activity, illustrating how computational peptide discovery can support β-lactam antibiotic resistance research.

• GANT61 Workflows for GLI-Driven Cancer Research

  2026-09-16

  GANT61 provides a practical way to test whether GLI1/GLI2 activity sustains malignant phenotypes, ferroptosis resistance, or chemotherapy tolerance. This guide connects formulation, dose-response design, GLI2–PRDX1 mechanism testing, combination assays, and tumor-model translation.

• Magneto-Piezoelectric Scaffolds for Infectious Bone Repair

  2026-09-15

  This ACS Nano study developed a dual-responsive scaffold that combines biofilm disruption with immune-metabolic stimulation for infectious bone defect repair. Its central advance is the targeted activation of oxidative phosphorylation in Icam1+ macrophages through sequential magnetic and ultrasound cues, linking JAK2-STAT3 signaling to improved osteogenic and proangiogenic repair.

• Gefitinib in Gastric Cancer Assembloid Assays

  2026-09-15

  Gefitinib (ZD1839) is a potent EGFR inhibitor whose effects can change substantially when tumor cells are tested with patient-matched stromal populations. This guide translates recent gastric cancer assembloid findings into practical assay decisions for pathway engagement, resistance analysis, and biologically interpretable drug screening.

• CHIR-99021 for Stem Cell and WNT Assays

  2026-09-14

  CHIR-99021 (CT99021) gives researchers a selective way to perturb GSK-3 while tuning pluripotency, lineage differentiation, and WNT-responsive degradation assays. This guide connects practical dosing and storage decisions with the KIF26B reporter strategy described in the reference study.

• Ginsenoside Rb1, Wnt Signaling, and Stroke Injury

  2026-09-14

  Liu et al. show that ginsenoside Rb1 limits cerebral ischemia-reperfusion injury by activating Wnt/β-catenin signaling and shifting microglia toward an anti-inflammatory phenotype. Using complementary mouse and BV2-cell models, the study links pathway activation to improved perfusion, smaller infarcts, and better neurological outcomes, while pharmacological pathway inhibition weakens these effects.

• Proteomimetics Target SARS-CoV-2 S-RBD/hACE2

  2026-09-13

  The reference study presents a structure-guided strategy for converting key hACE2 recognition elements into constrained proteomimetics that disrupt the SARS-CoV-2 Spike receptor-binding domain interaction. Its lead construct, compound 28, combined helical and β-sheet mimetics, inhibited pseudovirus entry, and showed stability and low epithelial permeability consistent with potential intranasal delivery.

• Berberine Hydrochloride: Metabolic and Bone Research

  2026-09-12

  Berberine hydrochloride is an isoquinoline alkaloid used in metabolic, antimicrobial, apoptosis, ferroptosis, and gut–bone research. Current evidence supports AMPK-centered cellular studies and a preclinical gut–bone mechanism, but it does not establish a clinical type 2 diabetes mellitus treatment or osteoporosis indication.

• Ertugliflozin (PF-04971729): From Transporter to Outcomes

  2026-09-11

  Ertugliflozin (PF-04971729) connects selective renal glucose reabsorption inhibition with cardiorenal outcome research. This evidence-first guide shows how to align transporter assays, clinical endpoints, and emerging ulcerative colitis models without overextending the data.

8139 records 1/543 page Next 12345 下5页 Last page